Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.
作者信息
Rastellini C, Salam A, Kuddus R, Aitouche A, Subbotin V, Braun M, Leach R, Peach R, Fung J J, Starzl T E, Rao A S
机构信息
Section of Cellular Transplantation, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pennsylvania, USA.
出版信息
Transplant Proc. 1999 Feb-Mar;31(1-2):1242-3. doi: 10.1016/s0041-1345(98)01979-4.
Abstract
摘要
相似文献
1
Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.
Transplant Proc. 1999 Feb-Mar;31(1-2):1242-3. doi: 10.1016/s0041-1345(98)01979-4.
2
Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
Transplant Proc. 1999 Feb-Mar;31(1-2):1244. doi: 10.1016/s0041-1345(98)01980-0.
3
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
Science. 1992 Aug 7;257(5071):789-92. doi: 10.1126/science.1323143.
4
5
Prolongation of allograft survival of transfected islets expressing human CTLA4-Ig, human soluble Fas ligand or a combination of the two.
Transplant Proc. 1998 Mar;30(2):534. doi: 10.1016/s0041-1345(97)01393-6.
6
Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.
Transplantation. 1997 Dec 27;64(12):1838-43. doi: 10.1097/00007890-199712270-00035.
7
An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection.
J Immunol. 2001 Sep 15;167(6):3478-85. doi: 10.4049/jimmunol.167.6.3478.
8
Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
Transplantation. 2001 Jun 15;71(11):1656-65. doi: 10.1097/00007890-200106150-00027.
9
Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice.
Transpl Immunol. 2001 Oct;9(1):51-6. doi: 10.1016/s0966-3274(01)00040-5.
10
Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation.
Transplantation. 1999 Feb 15;67(3):392-8. doi: 10.1097/00007890-199902150-00009.
引用本文的文献
1
Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.
Am J Transplant. 2008 Jun;8(6):1113-28. doi: 10.1111/j.1600-6143.2008.02219.x.
本文引用的文献
1
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.
J Immunol. 1997 Dec 1;159(11):5187-91.
2
Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.
Transplantation. 1997 Dec 27;64(12):1838-43. doi: 10.1097/00007890-199712270-00035.
3
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94. doi: 10.1073/pnas.94.16.8789.
4
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
Nature. 1996 May 30;381(6581):434-8. doi: 10.1038/381434a0.
Zotero 插件